| Androgen deprivation therapy for prostate cancer N Sharifi, JL Gulley, WL Dahut Jama 294 (2), 238-244, 2005 | 1257 | 2005 |
| Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer KH Chang, R Li, M Papari-Zareei, L Watumull, YD Zhao, RJ Auchus, ... Proceedings of the National Academy of Sciences 108 (33), 13728-13733, 2011 | 434 | 2011 |
| New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis Y Hou, J Zhao, W Martin, A Kallianpur, MK Chung, L Jehi, N Sharifi, ... BMC medicine 18, 1-8, 2020 | 406 | 2020 |
| Androgen signaling in prostate cancer C Dai, H Heemers, N Sharifi Cold Spring Harbor perspectives in medicine 7 (9), a030452, 2017 | 381 | 2017 |
| A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer KH Chang, R Li, B Kuri, Y Lotan, CG Roehrborn, J Liu, R Vessella, ... Cell 154 (5), 1074-1084, 2013 | 338 | 2013 |
| Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer Z Li, AC Bishop, M Alyamani, JA Garcia, R Dreicer, D Bunch, J Liu, ... Nature 523 (7560), 347-351, 2015 | 285 | 2015 |
| Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer A Hamada, T Sissung, DK Price, R Danesi, CH Chau, N Sharifi, D Venzon, ... Clinical cancer research 14 (11), 3312-3318, 2008 | 232 | 2008 |
| An update on androgen deprivation therapy for prostate cancer N Sharifi, JL Gulley, WL Dahut Endocrine-related cancer 17 (4), R305-R315, 2010 | 207 | 2010 |
| SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer M Yang, W Xie, E Mostaghel, M Nakabayashi, L Werner, T Sun, ... Journal of Clinical Oncology 29 (18), 2565, 2011 | 186 | 2011 |
| Hormonal therapy for prostate cancer K Desai, JM McManus, N Sharifi Endocrine reviews 42 (3), 354-373, 2021 | 178 | 2021 |
| DNA-PKcs-mediated transcriptional regulation drives prostate cancer progression and metastasis JF Goodwin, V Kothari, JM Drake, S Zhao, E Dylgjeri, JL Dean, ... Cancer cell 28 (1), 97-113, 2015 | 175 | 2015 |
| Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy Z Li, M Alyamani, J Li, K Rogacki, M Abazeed, SK Upadhyay, SP Balk, ... Nature 533 (7604), 547-551, 2016 | 167 | 2016 |
| A retrospective study of the time to clinical endpoints for advanced prostate cancer N Sharifi, WL Dahut, SM Steinberg, WD Figg, C Tarassoff, P Arlen, ... BJU international 96 (7), 985-989, 2005 | 143 | 2005 |
| Steroid biosynthesis and prostate cancer N Sharifi, RJ Auchus Steroids 77 (7), 719-726, 2012 | 140 | 2012 |
| HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study JWD Hearn, G AbuAli, CA Reichard, CA Reddy, C Magi-Galluzzi, ... The Lancet Oncology 17 (10), 1435-1444, 2016 | 131 | 2016 |
| Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer R Li, K Evaul, KK Sharma, KH Chang, J Yoshimoto, J Liu, RJ Auchus, ... Clinical cancer research 18 (13), 3571-3579, 2012 | 119 | 2012 |
| Mechanisms of androgen receptor activation in castration-resistant prostate cancer N Sharifi Endocrinology 154 (11), 4010-4017, 2013 | 106 | 2013 |
| Molecular pathways: inhibiting steroid biosynthesis in prostate cancer R Ferraldeschi, N Sharifi, RJ Auchus, G Attard Clinical cancer research 19 (13), 3353-3359, 2013 | 106 | 2013 |
| Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer J Li, M Alyamani, A Zhang, KH Chang, M Berk, Z Li, Z Zhu, M Petro, ... Elife 6, e20183, 2017 | 97 | 2017 |
| Generation of dynorphin knockout mice N Sharifi, N Diehl, L Yaswen, MB Brennan, U Hochgeschwender Molecular brain research 86 (1-2), 70-75, 2001 | 95 | 2001 |
